Related Experiment Video
Updated: May 17, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Targeting the global regulator Lsr2 as a novel approach for anti-tuberculosis drug development
1Department of Molecular Genetics, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8, Canada. jun.liu@utoronto.ca
Abstract:
Leprosy serum reactive clone 2 (Lsr2; Rv3597c) is a recently identified nucleoid-associated protein that acts as a global transcriptional regulator of Mycobacterium tuberculosis. Strikingly, Lsr2 appears to play a critical role in controlling the expression of virulence-associated genes. Here the authors outline the current knowledge concerning this novel global regulator and its potential as a target for chemotherapeutic intervention. Compounds that induce high level expression of lsr2 may lead to abolishment of virulence traits and render the bacterium incapable of causing infection and/or disease. Alternatively, compounds that either silence lsr2 expression or block the protein's function could be lethal since it has been postulated that lsr2 is essential in M. tuberculosis.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pharmacogenomics: Identification of New Drug Targets
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

